CD20, Kolumvi, Farashin DLBCL, Gaskiya
Glofitamab-gxbm an amince da shi ta FDA don zaɓaɓɓen ƙwararrun ƙwayoyin lymphomas na B-cell da suka koma baya.
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell ly..
Kwayar B-cell, Farashin DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin
Polatuzumab vedotin-piiq ya amince da USFDA don a baya wanda ba a kula da shi ba babban lymphoma na B-cell, ba a kayyade ba, da kuma babban darajar B-cell lymphoma
Mayu 2023: Ga manya marasa lafiya tare da babban matakin B-cell lymphoma (HGBL), ba a kayyade ba (NOS), ko kuma yada manyan ƙwayoyin lymphoma B-cell (DLBCL) waɗanda ba a taɓa samun magani ba kuma waɗanda ke da Inde Prognostic Inde.
Mota-T Ciwon ƙwayar cuta, Abubuwan da aka bayar na CARsgen Therapeutics Co., Ltd, Kamfanin Daiichi Sankyo, Farashin DLBCL, Binciken Gaggawa, Limited, Novartis AG
Kasuwar jiyya ta CAR T-Cell za ta yi girma cikin ƙimar ban mamaki a cikin shekaru 8 masu zuwa
Yuli 2022: Dangane da binciken da aka yi kwanan nan wanda Binciken Emergen ya gudanar, kasuwar duniya don maganin CAR T-cells ya kai girman dala biliyan 1.29 a cikin 2021 kuma ana sa ran yin rijistar kudaden shiga CAGR na kashi 24.9.
Burkitt lymphoma, Burkitt-kamar lymphoma, Farashin DLBCL, Gaskiya, Rituxan, Rituximab
Rituximab plus chemotherapy an amince da ita ta FDA don alamun ciwon daji na yara
Maris 2022: Hukumar Abinci da Magunguna ta amince da rituximab (Rituxan, Genentech, Inc.) tare da haɗin gwiwar chemotherapy don CD20-positive diffuse big B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
ADC Magungunan SA, wakilin alkylating conjugate, CD19 mai sarrafa garkuwar jiki, yaduwar ƙwayar cuta ta ƙwayar cuta ta B-sel, Farashin DLBCL, lymphoma B-cell mai girma, Babban lymphoma B-cell, Loncastuximab tesirine-lpyl, Zynlonta
FDA ta ba da izinin haɓakar loncastuximab tesirine-lpyl don babban lymphoma B-cell
Agusta 2021: FDA ta ba da loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), rigakafin CD19 da wakilin alkylating conjugate, hanzarta amincewa ga marasa lafiya marasa lafiya tare da sake dawowa ko rashin jin daɗi babban B-cell ly ..
Farashin DLBCL, Lymphoma na Hodgkin, linzoma, NHL, Non Hodgkin lymphoma
Me yasa samari ke da yawan kamuwa da cutar lymphoma?
Mutanen Lymph suna da ƙarancin ilimin lymph. Wuya, makwancin gwaiwa, da hammata duk su ne lymph. Idan akwai matsala a cikin tsarin lymphatic, toxin jiki za a adana a cikin jiki da yawa, kuma lymphoma zai yi sauri.